Department of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Heping District 110001, China.
Mediators Inflamm. 2019 Oct 24;2019:5617431. doi: 10.1155/2019/5617431. eCollection 2019.
Tofacitinib is a novel therapy for rheumatoid arthritis (RA). The aim of this study was to measure various serum cytokines levels and to explore potential markers predictive of therapeutic efficacy of tofacitinib for RA patients.
Thirty-two patients with RA were given tofacitinib (5 mg bid). Serum cytokines levels of Th1 (IFN-), Th2 (IL-6), Th17 (IL-17), Tregs (IL-35), and TNF- were detected by enzyme-linked immunosorbent assays.
Disease activity was significantly decreased as early as week 4 after tofacitinib treatment. Serum IL-35 levels were significantly increased and serum levels of TNF-, IL-17, IL-6, and IFN- were significantly reduced in response to tofacitinib since week 4.
After treatment with tofacitinib, RA patients may benefit from monitoring of disease activity as early as week 4. IL-35 also might be a predictive indicator of the disease activity and drug efficacy. Meanwhile, tofacitinib might be CS-sparing in RA.
托法替布是一种治疗类风湿关节炎（RA）的新型疗法。本研究旨在测量各种血清细胞因子水平，并探索托法替布治疗 RA 患者的疗效的潜在预测标志物。
32 例 RA 患者给予托法替布（5mg，bid）。采用酶联免疫吸附试验检测 Th1（IFN-）、Th2（IL-6）、Th17（IL-17）、Tregs（IL-35）和 TNF-的血清细胞因子水平。
托法替布治疗 4 周后疾病活动度显著降低。从第 4 周开始，血清 IL-35 水平显著升高，TNF-、IL-17、IL-6 和 IFN-水平显著降低。
RA 患者在接受托法替布治疗后，可能会受益于第 4 周即可监测疾病活动度。IL-35 也可能是疾病活动度和药物疗效的预测指标。同时，托法替布可能对 CS 具有节约作用。
